Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: A randomized placebo. Controlled clinical trial

Complementary Therapies in Medicine

Volumn 21, Issue 5, 2013, Pages 441-446

  Kianbakht, S ^a   Dabaghian, F Hashem ^b  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Hyperlipidemia; Patient; Salvia officinalis L.

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; SALVIA OFFICINALIS EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; IRAN; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLANT LEAF; RANDOMIZED CONTROLLED TRIAL; SALVIA OFFICINALIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES MELLITUS; HYPERLIPIDEMIA; PATIENT; SALVIA OFFICINALIS L.;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; IRAN; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; PLANT EXTRACTS; PLANT LEAVES; SALVIA OFFICINALIS;

EID: 84884142887     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2013.07.004     Document Type: Article

References (35)

1. Bell D.S., Al Badarin F., O'Keefe J.H. Therapies for diabetic dyslipidemia. Diabetes, Obesity and Metabolism 2010, 13:313-325.
2. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007, 67:997-1026.
3. Stolar M.W. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clinic Proceedings 2010, 85(Suppl.):S50-S59.
4. Philippe J., Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents?. International Journal of Clinical Practice 2009, 63:321-332.
5. Burnett J.R., Watts G.F. MTP inhibition as a treatment for dyslipidemias: time to deliver or empty promises?. Expert Opinion in Therapeutic Targets 2007, 11:181-189.
6. Cheatham W.W. Peroxisome proliferator-activated receptor translational research and clinical experience. American Journal of Clinical Nutrition 2010, 91:262S-266S.
7. van Bilsen M., van Nieuwenhoven F.A. PPARs as therapeutic targets in cardiovascular disease. Expert Opinion in Therapeutic Targets 2010, 14:1029-1045.
8. Derosa G., Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Current Molecular Pharmacology 2012, 5:272-281.
9. Huang T.H.W., Kota B.P., Razmovski V., Roufogalis B.D. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic and Clinical Pharmacology and Toxicology 2005, 96:3-14.
10. Tundis R., Loizzo M.R., Menichini F. Natural products as alpha-amylase and alpha-glucosidase inhibitors and their hypoglycemic potential in the treatment of diabetes: an update. Mini Reviews in Medicinal Chemistry 2010, 10:315-331.
11. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prevntive Cardiology 2000, 3:24-32.
12. Tapsell L.C., Hemphill I., Cobiac L., Patch C.S., Sullivan D.R., Fenech M., et al. Health benefits of herbs and spices: the past, the present, the future. Medical Journal of Australia 2006, 185(Suppl. 4):S4-S24.
13. Balakumar P., Rose M., Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?. Pharmacology 2007, 80:1-10.
14. Zargari A. Medicinal plants 1997, Vol. 4:59-64. Tehran University Publications, Tehran. 6th ed.
15. Rau O., Wurglics M., Paulke A., Zitzkowski J., Meindl N., Bock A., et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Medica 2006, 72:881-887.
16. Christensen K.B., Jorgensen M., Kotowska D., Petersen R.K., Kristiansen K., Christensen L.P. Activation of the nuclear receptor PPARγ by metabolites isolated from sage (Salvia officinalis L.). Journal of Ethnopharmacology 2010, 132:127-133.
17. Ninomiya K., Matsuda H., Shimoda H., Nishida N., Kasajima N., Yoshino T., et al. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorganic and Medicinal Chemisrty Letters 2004, 14:1943-1946.
18. Oboh G., Henle T. Antioxidant and inhibitory effects of aqueous extracts of Salvia officinalis leaves on pro-oxidant-induced lipid peroxidation in brain and liver in vitro. Journal of Medicinal Food 2009, 12:77-84.
19. Oniga I., Parvu A.E., Toiu A., Benedec D. Effects of Salvia officinalis L. extract on experimental acute inflammation. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2007, 111:290-294.
20. Eidi M., Eidi A., Zamanizadeh H. Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozocin-induced diabetic rats. Journal of Ethnopharmacology 2005, 100:310-313.
21. Lima C.F., Azevedo M.F., Araujo R., Fernandes-Ferreira M., Pereira-Wilson C. Metformine-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention?. British Journal of Nutrition 2006, 96:326-333.
22. Sa C.M., Ramos A.A., Azevedo M.F., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Sage tea drinking improves lipid profile and antioxidant defenses in humans. International Journal of Molecular Sciences 2009, 10:3937-3950.
23. Kianbakht S., Abasi B., Perham M., Hashem Dabaghian F. Anti-hyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double-blind placebo-controlled clinical trial. Phytotherapy Research 2011, 25:1849-1853.
24. Ozkan G., Sagdic O., Ekici L., Ozturk I., Ozcan M.M. Phenolic compounds of Origanum sipyleum L. extract, and its antioxidant and antibacterial activities. Journal of Food Lipids 2007, 14:157-169.
25. Han J., Weng X., Bi K. Antioxidants from a Chinese medicinal herb - Lithospermum erythrorhizon. Food Chemistry 2008, 106:2-10.
26. Yoo K.M., Lee C.H., Lee H., Moon B., Lee C.Y. Relative antioxidant and cytoprotective activities of common herbs. Food Chemistry 2008, 106:929-936.
27. Kim D.O., Jeong S.W., Lee C.Y. Antioxidant capacity of phenolic phytochemicals from various cultivars of plums. Food Chemistry 2003, 81:321-326.
28. The United States Pharmacopoeial Convention. USP 2004, 2094-2095. Webcom Limited, Toronto. 28th ed.
29. Ansley D.M., Wang B. Oxidative stress and myocardial injury in the diabetic heart. Journal of Pathology 2013, 229:232-241.
30. Davidson M.H., Toth P.P. Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases 2004, 47:73-104.
31. Moon Y.S., Kashyap M.L. Pharmacologic treatment of type 2 diabetic dyslipidemia. Pharmacotherapy 2004, 24:1692-1713.
32. Bays H., Stein E.A. Pharmacotherapy for dyslipidemia - current therapies and future agents. Expert Opinion in Pharmacotherapy 2003, 4:1901-1938.
33. Fung E.C., Crook M.A. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovascular Therapy 2012, 30:e212-e218.
34. Najafian M., Ebrahim-Habibi A., Yaghmaei P., Parivar K., Larijani B. Core structure of flavonoids precursor as an anti-hyperglycemic and anti-hyperlipidemic agent: an in vivo study in rats. Acta Biochimica Polonica 2010, 57:553-560.
35. Alcaraz M., Acevedo C., Castillo J., Benavente-Garcia O., Armero D., Vicente V., et al. Liposoluble antioxidants provide an effective radioprotective barrier. British Journal Radiology 2009, 82:605-609.